Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Vaccine competition?

<< Previous

Bullboard Posts

Next >>

Comment by Yajneon Feb 12, 2022 9:17pm

447 Views

Post# 34423824

RE:RE:Vaccine competition?

Another great post CancerSlayer!!!

CancerSlayer wrote:
Hi Apophis...Some thoughts: Don't see why the inhaled route cannot also be a viable option for TLT to investigate. Such a route can be used as both a therapeutic & as a vaccine. The big advantage here is you can directly target a virus therapeutically or you can elicit a strong local immune response directly at the site of initial infection. This approach would activate that all important mucosal immunity in addition to all the other players in the immune response.

As mentioned in the last NR, TLD-1433/PDT fully (or 99.99%) inactivated Covid & left the spike protein intact, including its many inherent epitopes (antibody attachment sites). As I mentioned before, I consider this a "giant" first step as often the spike protein & its epitopes can become destroyed or can lose their shape when removed from the virus during the inactivation process.

Now you just need a vector (a phage particle or an attenuated/modified virus) to deliver the goods (purified epitopes, etc.) in a proper diluent. I personally think this approach would be an excellent/viable option considering that there are already multiple efficacious mRNA/other injectable vaccines currently on the market. Also, I believe an inhalable vaccine doesn't need the special handling/refrigeration required by the mRNA vaccines, which means you can also more easily distribute such a vaccine to more rural, remote & many underserved communities.

The only caveat I would have also relates to its major benefit...the fact that it is inhaled. Although one can easily teach a capable person how to use an inhaler, can the vaccine's advantages be maintained when used in children, various elderly & certain other compromised patient populations...vaccine deposition in the upper airway could be lessened or at least variable in these patients. This is perhaps where a positive pressure mechanism of inhaled delivery could be utilized for some.

Sorry for the rambling, but I think this strategy deserves further exploration at some point by TLT. JMO & good luck...